17:00 EDT CG Oncology (CGON) files automatic mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Promising Clinical Data and Strong Financials Support Buy Rating for CG Oncology
- CG Oncology reports FY24 EPS ($1.41) vs ($15.65) last year
- Promising Phase 3 Trial Results and Strong Market Potential Drive Buy Rating for CG Oncology
- Buy Rating for CG Oncology: Promising Phase 3 Results and Strong Safety Profile of Cretostimogene
- Buy Rating for CG Oncology Backed by Promising Phase 3 Study Results and Strong Safety Profile